Core Insights - PacBio reported an adjusted loss per share of 12 cents in Q3 2025, an improvement from a loss of 17 cents per share in the previous year, exceeding the Zacks Consensus Estimate by 25% [1] - Total revenues for the quarter were $38.4 million, down 3.8% year over year, missing the Zacks Consensus Estimate by 3.5% [2] Revenue Breakdown - Revenues from the Americas were $18.1 million, a decrease of 10% year over year, attributed to cautious academic capital spending affecting demand for Revio systems [3] - Asia-Pacific revenues were $9.6 million, reflecting an 11% decline year over year, primarily due to fewer Revio placements and lower-than-expected average selling prices (ASPs) [4] - EMEA region revenues increased by 18% year over year to $10.7 million, driven by approximately 50% growth in consumables [5] Segment Analysis - Total product revenues were $32.6 million, down 7.7% from the previous year, with instrument revenues falling 32.7% to $11.3 million due to lower Revio system shipments [6] - Consumables revenues rose by 15.1% to $21.3 million, with annualized Revio pull-through per system at $236,000 [7] - Service and other revenues totaled $5.8 million, up 25.1% year over year, driven by increased service contract revenues related to Revio [9] Margin and Expense Trends - Adjusted gross profit increased by 24.3% year over year to $16.2 million, with adjusted gross margin expanding by 950 basis points to 42% [10] - Total operating loss was $38.9 million, significantly reduced from $64.1 million in the prior year [11] Financial Position - PacBio ended Q3 2025 with cash and investments totaling $298.7 million, down from $314.7 million at the end of Q2 2025 [12] Future Guidance - For Q4 2025, management expects revenues to grow by 10% compared to Q3 2025, with a Zacks Consensus Estimate of $41.9 million [13] - The revenue outlook for 2025 has been revised to between $155 million and $160 million, down from a previous range of $155 million to $165 million [14] Technological Advancements - PacBio introduced SPRQ-Nx sequencing chemistry, aimed at reducing long-read sequencing costs significantly [18] - The Sequel II CNDx system received Class III Medical Device Registration in China, marking a milestone in clinical-grade long-read sequencing [19] - The Revio system was selected for significant population-scale initiatives, indicating growing confidence in its capabilities for large-scale research [20]